| Literature DB >> 35204030 |
Piotr Podwalski1, Ernest Tyburski2, Krzysztof Szczygieł1, Krzysztof Rudkowski1, Katarzyna Waszczuk1, Wojciech Andrusewicz3, Jolanta Kucharska-Mazur1, Anna Michalczyk1, Monika Mak2, Katarzyna Cyranka4,5, Błażej Misiak6, Leszek Sagan3, Jerzy Samochowiec1.
Abstract
The superior longitudinal fasciculus (SLF) is a white matter bundle that connects the frontal areas with the parietal areas. As part of the visuospatial attentional network, it may be involved in the development of schizophrenia. Deficit syndrome (DS) is characterized by primary and enduring negative symptoms. The present study assessed SLF integrity in DS and nondeficit schizophrenia (NDS) patients and examined possible relationships between it and psychopathology. Twenty-six DS patients, 42 NDS patients, and 36 healthy controls (HC) underwent psychiatric evaluation and diffusion tensor imaging (DTI). After post-processing, fractional anisotropy (FA) values within the SLF were analyzed. Psychopathology was assessed with the Positive and Negative Syndrome Scale, Brief Negative Symptom Scale, and Self-evaluation of Negative Symptoms. The PANSS proxy for the deficit syndrome was used to diagnose DS. NDS patients had lower FA values than HC. DS patients had greater negative symptoms than NDS patients. After differentiating clinical groups and HC, we found no significant correlations between DTI measures and psychopathological dimensions. These results suggest that changes in SLF integrity are related to schizophrenia, and frontoparietal dysconnection plays a role in its etiopathogenesis. We confirmed that DS patients have greater negative psychopathology than NDS patients. These results are preliminary; further studies are needed.Entities:
Keywords: deficit schizophrenia; dti; nondeficit schizophrenia; psychopathology; superior longitudinal fasciculus; white matter integrity
Year: 2022 PMID: 35204030 PMCID: PMC8870217 DOI: 10.3390/brainsci12020267
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Demographic and clinical characteristics of participants.
| Patients with Deficit Schizophrenia (DS) | Patients with Nondeficit Schizophrenia (NDS) | Healthy |
| ɳ2/ | ||
|---|---|---|---|---|---|---|
| Age: | 38.38 (6.47) | 38.61 (7.12) | 37.39 (7.82) | 0.30 a | 0.740 | 0.01 f |
| Years of education: | 12.28 (2.90) | 13.33 (2.58) | 14.53 (2.63) | 9.31 b | 0.010 | 0.09 g |
| Sex: female/male | 7/19 | 23/19 | 21/15 | 6.88 c | 0.032 | 0.22 h |
| Antipsychotic medications: | ||||||
| Atypical: | 18 (69.23) | 26 (61.90) | - | 2.12 c | 0.547 | 0.12 h |
| Atypical and typical: | 7 (26.93) | 12 (28.60) | - | |||
| Typical: | 0 (0.00) | 3 (7.10) | - | |||
| No medications: | 1 (3.84) | 1 (2.40) | - | |||
| Chlorpromazine equivalent (mg): | 698.73 (321.77) | 627.50 (303.75) | - | 0.92 d | 0.724 | 0.23 i |
| Duration of illness: | 16.92 (6.01) | 13.60 (4.90) | - | −2.31 e | 0.084 | 0.33 j |
| Exacerbation: | 5.62 (2.53) | 6.71 (5.11) | - | −0.19 e | 0.854 | 0.03 j |
| Global functioning in GAF: | 50.40 (15.14) | 58.53 (14.53) | - | −2.18 d | 0.099 | 0.54 i |
| PANSS (by [ | ||||||
| Positive Symptoms: | 7.46 (2.8) | 8.14 (4.5) | - | −0.12 e | 1.000 | 0.02 j |
| Negative Symptoms: | 22.81 (4.5) | 13.29 (4.3) | - | −5.98 e | 0.000 | 0.87 j |
| Disorganization: | 12.81 (3.5) | 11.21 (3.8) | - | −2.24 e | 0.100 | 0.32 j |
| Affect: | 8.58 (3.5) | 9.26 (3.6) | - | −0.93 e | 1.000 | 0.13 j |
| Resistance: | 4.38 (0.6) | 4.90 (2.5) | - | −0.17 e | 1.000 | 0.02 j |
| PANSS (by [ | ||||||
| Negative Symptoms: | 20.77 (4.1) | 12.93 (3.6) | - | −5.76 e | 0.000 | 0.83 j |
| BNSS total score: | 47.42 (9.6) | 19.48 (11.8) | - | −6.05 e | 0.000 | 0.88 j |
| SNS total score: | 22.54 (7.8) | 9.52 (6.9) | - | −5.35 e | 0.000 | 0.77 j |
BNSS = Brief Negative Symptom Scale. GAF = Global Assessment of Functioning. PANSS = Positive and Negative Syndrome Scale. SNS = Self-evaluation of Negative Symptoms. a One-way analysis of variance F-test. b Kruskal–Wallis H-test. c Chi-squared test. d Student’s t-test. e Mann–Whitney U-test. f Eta squared effect size: small (0.01–0.059), medium (0.06–0.139), large (0.14–1.00). g Epsilon squared effect size: small (0.10–0.29), medium (0.30–0.49), large (>0.50). h Cramér’s V effect size: small (0.20–0.49), medium (0.50–0.79), large (>0.80). i Cohen’s d effect size: small (0.20–0.49), medium (0.50–0.79), large (>0.80). j Wendt’s r rank-biserial correlation effect size: small (0.10–0.29), medium (0.30–0.49), large (>0.50).
Figure 1Fractional anisotropy (FA) of the superior longitudinal fasciculus (SLF) for all groups. Standard deviations (SD) are presented as bars. a Significant difference for ANOVA post hoc. b Significant difference after covarying sex for ANCOVA post hoc. * p < 0.05.